Integra LifeSciences (IART) Tops Q3 EPS by 2c; offers guidance

Integra LifeSciences (NASDAQ: IART) reported Q3 EPS of $0.41, $0.02 better than the analyst estimate of $0.39. Revenue for the quarter came in at $380.83 million versus the consensus estimate of $375.83 million.

GUIDANCE:

Integra LifeSciences sees Q4 2024 EPS of $0.81-$0.89, versus the consensus of $0.86. Integra LifeSciences sees Q4 2024 revenue of $441-451 million, versus the consensus of $446.8 million.

Integra LifeSciences sees FY2024 EPS of $2.41-$2.49, versus the consensus of $2.46. Integra LifeSciences sees FY2024 revenue of $1.609-1.619 billion, versus the consensus of $1.614 billion.

For earnings history and earnings-related data on Integra LifeSciences (IART) click here.

You May Also Be Interested In

• Primoris cuts 2026 outlook on renewables cost overruns, COO exits
• Lockheed Martin wins $83 million Army missile contract
• MacroGenics to receive $24.5M milestone from Sanofi on FDA approval